Airsculpt Technologies (AIRS) Company Report

AirSculpt Technologies reported Q3 2025 revenue of $35 million, a 17.8% decline versus the prior year quarter, and adjusted EBITDA of $3 million, with an 8.7% margin. The company updated its 2025 revenue outlook to approximately $153 million, down from previous guidance, and reiterated the low end of its adjusted EBITDA guidance at approximately $16 million.
The company is expanding and refining its strategy to focus on introducing new services to capture the GLP-1 market opportunity, enhancing its sales and marketing strategy, and maintaining financial discipline, which includes nearly $18 million in debt repayment year-to-date.
During Q3 2025, AirSculpt made the decision to close its London center, which was its only unprofitable center, resulting in a $2.3 million loss related to its closure. Additionally, a $4.6 million non-cash impairment charge was recorded for a Salesforce technology project.
Michael Arthur will join AirSculpt as Chief Financial Officer in January 2026, succeeding Dennis Dean, and Dr. Aaron Rollins has resigned from the board.

Nov 7, 2025, 1:30 PM

AirSculpt Technologies Reports Q3 2025 Results and Updates 2025 Guidance

AIRS

Earnings

Guidance Update

Management Change

AirSculpt Technologies reported Q3 2025 revenue of $35 million, a 17.8% decline versus the prior year quarter, and adjusted EBITDA of $3 million.
The company updated its 2025 revenue outlook to approximately $153 million (from a previous range of $160-$170 million) and reiterated the low end of its adjusted EBITDA guidance at approximately $16 million.
Strategic initiatives include introducing new services like skin tightening and skin excisions to address the GLP-1 market opportunity, enhancing sales and marketing, and maintaining financial discipline.
In Q3, the company closed its London center, resulting in a $2.3 million loss related to asset impairment and $1 million in accelerated lease amortization.
Michael Arthur will join as Chief Financial Officer in January 2026, and Dr. Aaron Rollins resigned from the board.

Nov 7, 2025, 1:30 PM

AirSculpt Technologies Reports Q3 2025 Results and Updates 2025 Guidance

AIRS

Earnings

Guidance Update

Demand Weakening

AirSculpt Technologies reported Q3 2025 revenue of $35 million, a 17.8% decline versus the prior year quarter, and Adjusted EBITDA of $3 million, with an 8.7% margin.
The company updated its 2025 revenue outlook to approximately $153 million (down from previous guidance of $160 million-$170 million) and reiterated the low end of its Adjusted EBITDA guidance at approximately $16 million.
A key strategic focus is on capturing the GLP-1 market opportunity by introducing new services like skin tightening and skin excisions, with pilots showing higher conversion rates among GLP-1 patients.
AirSculpt closed its London center in Q3, resulting in a $2.3 million loss related to asset impairment, and has repaid nearly $18 million of debt year to date.
Michael Arthur will join as Chief Financial Officer in January 2026, succeeding Dennis Dean, and Dr. Aaron Rollins resigned from the board.

Nov 7, 2025, 1:30 PM

AirSculpt Technologies Reports Q3 2025 Results and Updates 2025 Guidance

AIRS

Earnings

Guidance Update

Management Change

AirSculpt Technologies reported a 17.8% decline in revenue to $35.0 million for the third quarter ended September 30, 2025, compared to $42.5 million in the prior year. The company also recorded a net loss of $9.5 million and Adjusted EBITDA of $3.0 million for the quarter.
For the first nine months of 2025, revenue declined 16.1% to $118.4 million, and the net loss was $13.0 million.
The company updated its full-year 2025 guidance, projecting revenue of approximately $153 million (down from a previous range of $160 million to $170 million) and Adjusted EBITDA of approximately $16 million.
As of September 30, 2025, AirSculpt had $5.4 million in cash and cash equivalents and reduced debt by $18 million year-to-date.
Michael Arthur has been appointed as the new Chief Financial Officer, with his start date set for January 5, 2026.